Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2025 | Investigating resistance to menin inhibitors in AML: mechanisms and ongoing research

Amir Fathi • 5 Sep 2025
SOHO 2025
Acute Myeloid Leukemia Leukemia

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses resistance to menin inhibitors in acute myeloid leukemia (AML), highlighting MEN1 mutations as one potential mechanism. He notes that ongoing research aims to identify strategies, including novel combinations, to overcome resistance. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Amir Fathi

Community-academic collaboration in AML management
1:08
Community-academic collaboration in AML management
Amir Fathi • 21 Sep 2026
Sequencing targeted therapies in AML with multiple targetable alterations
0:51
Sequencing targeted therapies in AML with multiple targetable alterations
Amir Fathi • 21 Sep 2026
KOMET-007 trial results: ziftomenib combinations in NPM1-mutated and KMT2A-rearranged AML
1:31
KOMET-007 trial results: ziftomenib combinations in NPM1-mutated and KMT2A-rearranged AML
Amir Fathi • 21 Sep 2026
Key advances shaping frontline treatment for AML
1:19
Key advances shaping frontline treatment for AML
Amir Fathi • 13 Jun 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals